Plenary Session:
8. Special Plenary Session: Emerging Infections
Wednesday, October 2, 2013: 3:45 PM-5:45 PM
Room: The Moscone Center: Esplanade Ballroom 301-310

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the challenges faced by physicians managing patients with severe novel clinical syndromes
  • discuss the lessons that can be learned from formal and systematic clinical investigation of emerging infectious disease
  • discuss how clinical experience in dispersed localities can be globally  applied
  • describe critical role of communication in instilling trust during outbreaks caused by new or novel agents
  • identify strategies for addressing communication challenges

Target Audience: vaccinologists, scientists, researchers, public health practitioners, pharmacists, nurses, microbiologists, members-in-training, lab personnel, investigators, infectious diseases physicians, infectious diseases pediatricians, infection preventionists, hospital epidemiologists, hospital administrators, HIV specialists, HIV clinicians, health care workers, fellows, epidemiologists, clinicians, academicians

Tracks: Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

Moderators:  Robert Read, MD, FIDSA, University of Southampton , Scott Fridkin, MD, Centers for Disease Control and Prevention , Joel Gallant, MD, MPH, FIDSA, Southwest Care Center and Penelope H. Dennehy, MD, FIDSA, The Alpert Medical School of Brown University

Presentations:

3:55 PM
Presenting the IDSA Alexander Fleming Award
David A. Relman, MD, FIDSA

4:00 PM
Presenting the SHEA Investigator Award
John A. Jernigan, MD, MS

4:05 PM
Presenting the HIVMA HIV Clinical Educator Award
Michael Horberg, MD, MAS, FIDSA

4:10 PM
Presenting the PIDS Distinguished Service Award
David W. Kimberlin, MD, FIDSA

4:35 PM
29b

5:25 PM
Q&A

CME Credits: Maximum of 2.0 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 2.0 knowledge-based contact hours (0.2 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-132-L01-P

Disclosures:

R. Read, Novartis vaccines and diagnostics: Scientific Advisor, Consulting fee

S. Fridkin, None

J. Gallant, Gilead Sciences: Investigator and Scientific Advisor, Consulting fee and Research grant
Bristol-Myers Squibb: Scientific Advisor, Consulting fee
Merck & Co.: Scientific Advisor, Consulting fee
Janssen Therapeutics: Scientific Advisor, Consulting fee
Takara Bio, Inc.: Scientific Advisor, Consulting fee

P. H. Dennehy, None

R. Besser, None

Z. A. Memish, None

D. L. Swerdlow, None

D. A. Relman, None

M. Horberg, None

D. W. Kimberlin, GSK: Grant Investigator, Grant recipient and I serve as one of dozens of sites on clinical trials conducted by GSK. All monies go directly to my university and not to me.
Giliead: Grant Investigator, Grant recipient and I serve as one of dozens of sites on clinical trials conducted by Gilead. All monies go directly to my university and not to me.

See more of: Plenary Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.